These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension]. Saji T; Ozawa Y; Nakayama T; Matsuura H; Hashiguchi R; Matsuo N; Muto H; Yamazaki J; Morishita T; Saito T J Cardiol; 1996 Apr; 27(4):197-205. PubMed ID: 8642506 [TBL] [Abstract][Full Text] [Related]
5. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Galiè N; Humbert M; Vachiéry JL; Vizza CD; Kneussl M; Manes A; Sitbon O; Torbicki A; Delcroix M; Naeije R; Hoeper M; Chaouat A; Morand S; Besse B; Simonneau G; J Am Coll Cardiol; 2002 May; 39(9):1496-502. PubMed ID: 11985913 [TBL] [Abstract][Full Text] [Related]
6. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
7. Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. Sakao S; Tanabe N; Kasahara Y; Tatsumi K Intern Med; 2012; 51(19):2721-6. PubMed ID: 23037462 [TBL] [Abstract][Full Text] [Related]
8. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. Nagaya N; Uematsu M; Okano Y; Satoh T; Kyotani S; Sakamaki F; Nakanishi N; Miyatake K; Kunieda T J Am Coll Cardiol; 1999 Oct; 34(4):1188-92. PubMed ID: 10520811 [TBL] [Abstract][Full Text] [Related]
9. [Effect of long-term therapy with oral Beraprost on survival of patients with arterial and inoperable thromboembolic pulmonary hypertension]. Kurzyna M; Florczyk M; Fijałkowska A; Kuca P; Szewczyk G; Burakowski J; Kober J; Sikora J; Wawrzyńska L; Szturmowicz M; Tomkowskil W; Torbicki A Pol Arch Med Wewn; 2004 Apr; 111(4):477-82. PubMed ID: 15517762 [TBL] [Abstract][Full Text] [Related]
10. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Kunieda T; Nakanishi N; Matsubara H; Ohe T; Okano Y; Kondo H; Nishimura M; Shirato K; Tanabe N; Homma S; Yoshida S; Inokuma S; Kodama M; Koike T; Hishida H Int Heart J; 2009 Jul; 50(4):513-29. PubMed ID: 19609055 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286 [TBL] [Abstract][Full Text] [Related]
12. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Vizza CD; Sciomer S; Morelli S; Lavalle C; Di Marzio P; Padovani D; Badagliacca R; Vestri AR; Naeije R; Fedele F Heart; 2001 Dec; 86(6):661-5. PubMed ID: 11711462 [TBL] [Abstract][Full Text] [Related]
13. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Melian EB; Goa KL Drugs; 2002; 62(1):107-33. PubMed ID: 11790158 [TBL] [Abstract][Full Text] [Related]
14. High Frequency of Acute Adverse Cardiovascular Events After Lung Transplantation in Patients With Pulmonary Arterial Hypertension Receiving Preoperative Long-Term Intravenous Prostacyclin. Akagi S; Oto T; Kobayashi M; Miyoshi K; Sugimoto S; Yamane M; Nakamura K; Sarashina T; Miyoshi S; Ito H Int Heart J; 2017 Aug; 58(4):557-561. PubMed ID: 28690295 [TBL] [Abstract][Full Text] [Related]